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Repeated infusion of Hexamoll® DINCH® for 4 weeks did not result in systemic toxicity.
300mg/kg bw/day, the highest dose level that could be tested was identiﬁed as NOAEL.
Effects seen are most likely related to exceeding intravasal solubility of the test substance.
Study supports the risk-/beneﬁt assessment for Hexamoll® DINCH® based medical devices.
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a b s t r a c t
Alternative plasticizers to di(2-ethylhexyl) phthalate (DEHP) for blood bags have been sought for many
years. Cyclohexane-1,2-dicarboxylic acid, diisononylester (Hexamoll® DINCH®) is an alternative that has
been evaluated in preliminary studies for compatibility and efﬁcacy to preserve whole blood. While
Hexamoll® DINCH® has an extensive database for mammalian toxicity via oral administration, data were
needed to evaluate toxicity from intravenous (IV) administration to support the use of the plasticizer
Hexamoll® DINCH® in blood bags. A series of studies was performed by slow IV injection or IV infu-
sion of Hexamoll® DINCH®, a highly viscous, hydrophobic substance, suspended in Intralipid® 20% (20%
intravenous fat emulsion). Rats were injected once, followed by 14 days of recovery; injected daily for
5 days followed by 5 days of recovery, or infused for 29 days (4h/day) followed by 14 days of recov-
ery. Dose levels were 0, 62, 125, and 250–300mg/kg body weight/day. These dose levels represent the
limits of suspension and far exceed any anticipated exposures from migration out of plasticized blood
bags. Animals were observed for signs of toxicity; body weight and feed consumption were measured;
blood collected for clinical chemistry and hematology; and tissues collected and processed for histopath-
ology. Special emphasis was placed on evaluating endpoints and tissues that are commonly associated
with plasticizer exposure in rodents. Urine was collected during the 4-week study to quantify urinary
metabolites of Hexamoll® DINCH®. The results of the studies indicate that no substance-related toxicity
occurred: no effects on behavior, no effects on organ weight, no effect on serum chemistry including
thyroid hormones; and no effect on major organs, especially no testicular toxicity and no indication for
peroxisome proliferation in the liver. The only effects seen were petechia and granulomas related to dis-
® ®sipation of suspendedHexamoll DINCH in the aqueous environment of the blood. However, the results
of metabolite analyses demonstrate that Hexamoll® DINCH® was bioavailable. Therefore, based on the
lack of Hexamoll® DINCH®-related systemic toxicity with the exception of the physical limitations, the
no-observed-adverse-effect level for parenterally administered Hexamoll® DINCH® is considered to be
300mg/kg bw/day.
© 2015 The Authors. Pu
∗ Correspondingauthor at: BASFSE, Industrial Petrochemicals Europe, Carl-Bosch-
trasse 38, 67056 Ludwigshafen, Germany.
E-mail address: rainer.otter@basf.com (R. Otter).
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c-nd/4.0/).blished by Elsevier Ireland Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. IntroductionEfforts to replace DEHP in products have been ongoing for some
time. For medical applications such as blood bags, these efforts are
complicated by the need to store blood for long periods of time,
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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omething that DEHP is able to do well. While there is one citrate-
ased substitute for DEHP in PVC (polyvinylchloride) blood bags
Patent EP0138147A2, 1985), industry has continued to evaluate
ther plasticizers. The issues for substitution range from ease of
drop-in” to efﬁcacy for blood storage. Hexamoll® DINCH® was
eveloped as a substitute plasticizer for “sensitive” applications: it
as a low toxicity; is not considered to be an endocrine-active sub-
tance (Furr et al., 2014); and has a low migration from PVC (Bhat
t al., 2014). Oral exposure was associated in rats with induction of
iver enzymes that are believed to have altered circulating thyroid
land hormones, resulting in an enlarged thyroid gland; this effect
s a secondary mechanism that is not considered to be relevant for
umans (European Food Safety Authority, 2006). No other target
issues have been identiﬁed, e.g., no effect on the testes or develop-
ng male reproductive tract, no induction of peroxisomal enzyme
ctivity. Thus, Hexamoll® DINCH® seems suitable for applications
here human exposure might be extensive. However, its efﬁcacy
or blood storage was unknown.
Dumont et al. (2012) demonstrated that Hexamoll® DINCH®
ould function well as a substitute for DEHP in blood bags
esulting in acceptable levels of hemolysis with little to no
igration from the PVC. The hemolysis rate is strongly depend-
ng on the additive solution used for collection of the blood
Lagerberg et al., 2015). When second generation additive solu-
ions like phosphate–adenine–glucose–guanosin–saline–mannitol
PAGGS-M), additive solution-3 (AS-3: glucose, sodium citrate,
odium chloride, phosphoric acid monosodium salt monohy-
rate, citric acid and adenine) or phosphate–adenine–glucose–
uanosin–gluconate–mannitol (PAGGG-M) were used instead of
AG-M (saline–adenine–glucose–mannitol), the hemolysis rate in
he Hexamoll® DINCH® based systems was equal to the DEHP
ased systems. The suitability of Hexamoll® DINCH® to protect
ed blood cells against hemolysis was conﬁrmed in a screening
tudy (Haishima et al., 2014) and reduced activation of platelets
as reported for Hexamoll® DINCH® based bags for the storage of
ediatric platelet concentrates in plasma (Nair et al., 2011; Zhong
t al., 2013). These observations prompted discussions with the US
ood and Drug Administration (FDA) regarding the evaluation of
examoll® DINCH® inbloodbag sets. AlthoughHexamoll® DINCH®
as an extensive database of mammalian toxicity data follow-
ng oral administration, the route of exposure will be intravenous
ased on its intended use in medical applications and a clear data
ap exists with respect to potential toxicity following intravenous
IV) administration. Therefore the purpose of these studies was to
valuate the potential toxicity of Hexamoll® DINCH® following IV
dministration to rats.
Injection or infusion of a hydrophobic substance such as
examoll® DINCH® canbeproblematic. Rubin (1975) reported that
% gum acacia or 4% serum albumin was inadequate to solubi-
ize DEHP, but solubilization in Tween 80 produced a transparent
uspension. However, both Rubin (1975) and Schulz et al. (1975)
eported hemorrhagic lungs in rats injectedwith >300mg/kg DEHP
olubilized in Tween 80. On the other hand, Cammack et al.
2003) injected up to 600mg/kg DEHP solubilized in Intralipid®
ithout any apparent effect on the lungs, and Wirnitzer et al.
2011) infused 380mg/kg di(2-ethylhexyl) terephthalate, another
ydrophobic substance, suspended in Lipofundin MCT10 with-
ut any apparent effect on the lungs. Therefore, intravenous
dministration could be conducted with Hexamoll® DINCH® by
uspending in an appropriate agent; Intralipid® 20% was selected
s the vehicle following the procedures used by Cammack et al.
2003).Based on FDA suggestions, 2 preliminary studies and a deﬁni-
ive study were conducted in rats: a single IV injection followed by
14-day recovery period, a 5-day repeated dose IV injection fol-
owed by a 5-day recovery, and a deﬁnitive 4-week repeated doseters 238 (2015) 100–109 101
IV infusion study followedby a 14-day recovery. Exposure to a plas-
ticizer in a PVC blood bag is often reﬂected in short-term exposure
(1–5days), and in somecases repeatedexposureover severalweeks
(FDA, 2002). In each study, particular attention was paid to target
tissues or endpoints that had been identiﬁed in oral toxicity stud-
ies associated with DEHP exposure. Furthermore, quantitation of
blood levels and urinary metabolites of Hexamoll® DINCH® were
included to better provide cross-over to the oral toxicity stud-
ies.
2. Materials and methods
2.1. Chemicals
Hexamoll® DINCH® (1,2-cyclohexane dicarboxylic acid,
di(isononyl) ester (CAS # 474919-59-0 (US); 166412-78-8 (outside
US)) was provided and certiﬁed >99.5% pure by BASF Corporation,
4403 LaPorte Rd., Pasadena, TX. Hexamoll® and DINCH® are
registered trademarks of BASF SE. Intralipid® 20% IV Fat Emulsion
was purchased from Fresenius Kabi, Three Corporate Drive, Lake
Zurich, IL 60047. All reagents for chemistries or biochemical
analyses were speciﬁed in standard operating procedures.
2.2. Dose preparation
Hexamoll® DINCH® was sterile-ﬁltered (0.22-m polyvinyli-
dene ﬂuoride ﬁltration unit) and aliquoted into sterile secondary
containers with sterile closures prior to further use. Dosing solu-
tions were prepared by adding Hexamoll® DINCH® to Intralipid®
20% to achieve the desired concentration (v/v). The mixture was
sonicated in an ice bath using a microtip Branson Digital Sonifer
450. The duration of sonication varied with the concentration, but
ranged from 5 to 10min at 20% ampliﬁcation. Dosing suspensions
were prepared daily under sterile conditions, and the suspensions
were agitated on a Vortex mixer prior to loading each syringe.
The concentration was veriﬁed by gas chromatography following
extraction with tetrahydrofuran.
2.3. Animals
Male and female Sprague-Dawley rats were obtained from
either Harlan, Haslett, MI (acute and 5-day conducted at Ibex Pre-
clinical Research) or Charles River Breeding Laboratories, Portage,
MI (4-week study conducted at Covance Laboratories). Animals
were allowed to acclimate for at least 5 days prior to randomiza-
tion and treatment. For the 4-week study, catheterswere surgically
implanted into the femoral vein by the vendor and the patency was
checked prior to initiation. All animals were at least 6 weeks of age
at initiation of dosing. Animals were restrained for injection, but
were not sedated. For infusion, catheters were tethered to allow
free movement of the animals.
2.4. Husbandry
Rats were housed individually in stainless steel cages and
offered Certiﬁed Rodent Diet ad libitum unless fasted for study
procedures. Tapwaterwasprovidedad libitum. Environmental con-
trols were set to maintain the following animal room conditions:
temperature range of 20–26 ◦C, relative humidity range of 30–70%,
10 or greater air changes/h, and a 12-h light/12-h dark cycle. Envi-
ronmental conditions were monitored continuously and recorded
at least daily. All husbandry procedures conformed to the National
Institutes of Health (NIH) Guide for the Care and Use of Laboratory
Animals, 8th ed.
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.5. Treatment
.5.1. Preliminary studies
Animals were randomized into groups based on body weight.
ach study included three treatment groups plus a vehicle control.
osage levelswere62.5, 125, and250–300mg/kg/d. Theconcentra-
ions were 5, 10, or 25mg/mL with a dosing volume of 12.5mL/kg
or injection or 12mL/kg for infusion. This volume has been used
uccessfully for injection into the tail vein (Diehl et al., 2001). Injec-
ions were performed into the tail vein over a 10-min period using
nfusion pumps. Animals were treated either all on a single day
single-dose study) or for 5 consecutive days. There were 10 males
nd 10 females per group, 5 per sex per group euthanized 24h
fter the last injection, the other 5 euthanized after the recovery
eriod (14 days for single injection, 5 days for 5-day repeated injec-
ion). Dose levels were selected based on the studies conducted by
ammack et al. (2003) and Wirnitzer et al. (2011).
.5.2. Deﬁnitive 4-week study
The study design was based on Organisation for Economic Co-
peration and Development (OECD) Guidelines for the Testing
f Chemicals, Section 4, Health Effects, No. 407 (1995); and on
he principles of the Food and Drug Administration Center for
rug Evaluation and Research (CDER)/International Conference on
armonisation (ICH) Harmonised Tripartite Guideline ICH-S7A,
afety Pharmacology Studies for Human Pharmaceuticals (CDER,
uly 2001). Animals were randomized into groups based on body
eight. Each study included three treatment groups plus a vehi-
le control. Dosage levels were 60, 125, and 300mg/kg/d. Infusions
ere performed via indwelling catheters into the femoral vein over
4-hperiodusing an infusionpump followedby infused saline over
he remainder of the 24h to maintain patency of the catheter. Ani-
als were treated daily for 29 days. There were 15 males and 15
emales per group for the control, low-dose and high-dose groups,
0 per sex per group euthanized 24h after the last infusion and the
ther 5 euthanized after the recovery period (14 days). The mid-
ose contained 10 males and 10 females euthanized 24h after the
ast infusion
.5.3. In-life observations and measurements
Animals were checked daily for clinical signs of toxicity. Body
eight and feed consumption were measured weekly. Animals
ere assessed for signs of neurotoxicity using a functional obser-
ational battery during the last week on test.
.5.4. Clinical chemistry, hematology, and urinalysis
Blood sampleswere collected from fasted animals at sacriﬁce for
ematology, coagulation, and clinical chemistry (including thyroid
ormone analysis-total triiodothyronine (T3), total thyroxine (T4)
nd total thyroid stimulating hormone (TSH)). Blood samples were
ollected from the jugular vein under anesthesia. Blood samples
or clinical chemistry (approximately 0.5–0.6mL) were placed into
ubes without anticoagulant, while samples for coagulation were
ollected into tubeswith sodium citrate and hematology into tubes
ithpotassiumethylenediaminetetraacetic acid (EDTA). Bloodwas
nalyzed for routine parameters as prescribed in the OECD Testing
uideline No. 407with the addition of thyroid gland hormones and
SH. Chemistries were determined using a Roche Modular PreAn-
lytics, while hematology was determined using either HEMAVET
50 FS or Advia 120/2120 hematology analyzer (Siemens Diagnos-
ics, Henkestrasse 127, D-91052 Erlangen, Germany). Thyroxine,
3 and TSH were determined using a Radioimmuno assay either
y Antech Diagnostic GLP, Morrisville, NC or solid-phase, com-
etitive chemiluminescent enzyme immunoassay using Immulite
000 (Siemens Diagnostics, Henkestrasse 127, D-91052 Erlangen,
ermany). Urine was tested for the presence of ketones, protein,ters 238 (2015) 100–109
andglucose, andexaminedmicroscopically for thepresenceof casts
and epithelial cells.
2.5.5. Blood collection for parent compound and metabolite
In the single-exposure study, blood was collected from 10 ani-
mals per sex from the high-dose group approximately 2h after
injection to quantify the concentration of Hexamoll® DINCH®.
Approximately 0.5mL of blood was obtained from the retro-orbital
sinus and placed into tubes with lithium heparin. Samples were
frozen at −80 ◦C and shipped on dry ice to Research Institute
for Chromatography, Kortrijk, Belgium, for analysis. Hexamoll®
DINCH® and its monoester metabolite MINCH were quantiﬁed
using internal standards (d4-DEHP and d4-MEHP) following ethyl-
acetate extraction of hemolysed blood. The dried residuewas taken
up into 100L acetonitrile and analyzed by liquid chromatogra-
phy with mass spectrometry (LC/MS–MS) using an Agilent 6460
triple quadrupole mass spectrometer equipped with electrospray
ionization (ESI) Jetstream. Metabolites were separated on a Zorbax
SB-CN (3.5mm i.d., 150mm length, 3.5m particles) column using
a gradient of acetonitrile starting from 10% in 10mM ammoniu-
macetate to 100% within 10min at a ﬂow of 0.65mL/min. For MS,
the gas ﬂowwas 11L/min, gas temperaturewas 310 ◦C. Fragmenter
voltage was 100V, Sheat gas temperature 250 ◦C with a sheat gas
ﬂow of 11 L/min. Hexamoll® DINCH® and d4-DEHP (corresponding
internal standard)weremeasured inpositive ionmonitoringmode,
MINCHandd4-MEHP (corresponding internal standard)weremea-
sured in negative ion monitoring mode. Both modes are acquired
simultaneously using +/− switching.
2.5.6. Urinary metabolite analysis
Urine samples for urinalysis were collected overnight on days 7,
14, 21, and 28 of the dosing phase of the deﬁnitive study and once
during the last week of the recovery phase from animals fasted
overnight. Urine samples were stored in a freezer, set to maintain
−60 to −80 ◦C, until packed on dry ice and shipped to the IPA
(Institute for Prevention and Occupational Medicine of the Ger-
man Social Accident Insurance – Institute of the Ruhr-University
Bochum), Germany, for analysis of urinary metabolites. Urinary
metabolites of Hexamoll® DINCH® were determined with online
solid phase extraction high pressure liquid chromatography–mass
spectrometry (HPLC–MS/MS) after enzymatic hydrolysis accord-
ing to Schütze et al. (2012) and Koch et al. (2013). Metabolite
cyclohexane-1,2-dicarboxylic acid (CHDA) was quantiﬁed with
cyclohexane-1,4-dicarboxylic acid as internal standard and not
via standard addition. All oxidized metabolites were quantiﬁed
as published via isotope dilution. The following metabolites were
quantiﬁed: CHDA cyclohexane-1,2-dicarboxylic acid; cx-MINCH
(cyclohexane-1,2-dicarboxylic acid, monocarboxyoctylester), OH-
MINCH (cyclohexane-1,2-dicarboxylic acid, monohydroxynony-
lester); Oxo-MINCH (cyclohexane-1,2-dicarboxylic acid, mono-
oxononylester); MCHpCH (cyclohexane-1,2-dicarboxylic acid,
monocarboxyheptylester); MCHxCH (cyclohexane-1,2-dicarboxy-
lic acid, monocarboxypentylester); and MCBCH (cyclohexane-1,2-
dicarboxylic acid monocarboxybutylester).
2.5.7. Necropsy and histopathology
Protocol-speciﬁed tissues consistent with the required tis-
sues speciﬁed in the OECD Guideline 407 from all animals at
scheduled and unscheduled necropsies were preserved in 10%
neutral-buffered formalin, with the exception of the eyes, optic
nerves, and Harderian glands, which were preserved in modi-
ﬁed Davidson’s ﬁxative and held in 10% neutral-buffered formalin.
Testes were preserved in Davidson’s ﬁxative. All tissues were
embedded in parafﬁn, sectioned, stained with hematoxylin and
eosin, and examined microscopically. Additionally, liver samples
fromall infused animalswere stained for lipofuscinusing Schmorl’s
R.M. David et al. / Toxicology Letters 238 (2015) 100–109 103
Table 1
Thyroid hormone in animals 24h after a single injection or 5 days of injection with Hexamoll® DINCH® .
Parameter Males Females
Control Low Mid High Control Low Mid High
Single injection
T3 (ng/dL) 61 ± 9 74 ± 10 66 ± 15 70 ± 8 68 ± 6 71 ± 8 66 ± 12 66 ± 11
T4 (g/dL) 4.6 ± 0.8 4.7 ± 0.3 5.1 ± 1.2 5.8* ± 0.8 3.3 ± 0.8 3.1 ± 0.5 3.7 ± 0.7 3.1 ± 0.9
TSH (ng/mL) 2.2 ± 0.8 4.5* ± 1.7 4.2 ± 2.0 3.0 ± 0.9 2.4 ± 0.3 2.3 ± 0.7 2.6 ± 1.3 10.7* ± 6.2
5 days of injection
T3 (ng/dL) 50 ± 5 51 ± 17 61 ± 8 50 ± 13 60 ± 19 56 ± 4 64 ± 11 57 ± 10
T4 (g/dL) 2.7 ± 0.6 2.9 ± 0.7 3.0 ± 0.6 2.9 ± 0.6 2.1 ± 0.3 1.5 ± 0.8 2.2 ± 0.7 1.4 ± 0.3
TSH (ng/mL) 4.0 ± 2.4 3.7 ± 1.7 4.3 ± 1.5 3.7 ± 1.6 1.1 ± 0.4 2.3 ± 2.0 1.7 ± 1.2 2.3 ± 0.9
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* Signiﬁcantly different from control, p≤0.05.
tain as an indicator of the presence of peroxisome proliferation. To
stablish thenatureof thegranulomasobserved in the lungs, spleen
nd liver, sections of these tissues were stained with oil red O stain
hich allows visualization of lipid.
In the 4-week study, unpreserved samples of the liver from
ll groups were frozen at −80 ◦C and shipped on dry ice to BASF
E for determination of cyanide-insensitive palmitoyl CoA Oxida-
ion enzyme activity according to the method of Lazarow (1981)
dapted toaCOBASFara II Instrument,Roche,Mannheim,Germany.
.6. Statistical methods
Data for each sex were analyzed separately; data collected
ere analyzed statistically using an analysis of variance (ANOVA)
nd Dunnett’s t-test. Non-parametric data were analyzed using a
ruskal–Wallis test. Signiﬁcance was determined by p<0.05.
. Results
.1. Preliminary studies
No mortality occurred and no signs of toxicity or differences in
odyweightwereobserved for either the singleor5-dayexposures.
Serum chemistries from animals euthanized one day or 14 days
fter a single dose of Hexamoll® DINCH® showed some statistically
igniﬁcant differences, but no biologically relevant differences. For
xample, levels of creatinine and calcium ion were statistically
igher in thehigh-dosemale groupon theday after treatment com-
ared with the control group (0.3mg/dL for control versus 0.4 for
igh dose for creatinine; 9.3mg/dL for control versus 9.9 for high
ose for calcium), and levels of phosphate and chloride ion in all
reated male groups were signiﬁcantly different from those in the
ontrol group (8.3 for control group versus 9.8mg/dL for treated
roups for phosphate; 103.8mg/dL for control group versus 107.2,
05.7, and 106.2 for low, mid, and high-dose groups for chloride).
one of these occurred in female groups or showed dose-related
rends. Because of the inconsistency of response within or between
exesor themagnitudeof the response (within1standarddeviation
f the control groupvalues), noneof these changeswere considered
iologically or toxicologically signiﬁcant.
Tri-iodothyronine levels were unchanged after a single expo-
ure, but were elevated 5 days after a 5-day exposure in male
ats injected with the mid- and high-dose of Hexamoll® DINCH®
Table 1). No effect was observed in female rats. Given the isolated
ffect, it is not considered to reﬂect treatment with Hexamoll®
INCH®. Likewise, serum levels of T4 were signiﬁcantly higher in
he high-dose male group compared with the control group the
ay after a single injection, but not 14 days later or in female rats.
or animals given a single injection, TSH was signiﬁcantly higher
n female high-dose animals one day after injection compared
ith the control group (there was no change in thyroxine levels,lating hormone.
however). The standard deviation was >50% indicating a high vari-
ability in the data. No differences in TSH levels were observed 14
days after injection or among male rats. Also, no differences in TSH
levels were observed after 5 days of injection in either sex. Because
the hormone levels were not consistently altered in both sexes or
in a dose-related manner, the ﬁndings were not considered to be
biologically relevant and the data are not presented. Furthermore,
elevations in T4 levels individually in the absence of other physi-
ological changes such as TSH are not common and not considered
biologically relevant (Bianco et al., 2014).
No consistent changes in hematology were observed after a
single injection. After 5 days of injection, platelet counts in the
female high-dose group were signiﬁcantly lower than for the con-
trol group the day following the last injection (756±79 thou/L
versus 918±40 for the control group), but signiﬁcantly not lower
after a 5 day recovery (1051±94 thou/L versus 918±40 for the
control group). All values were within normal range for the labo-
ratory. No effect was observed among male groups injected for 5
days (Table 2).
After a single injection of Hexamoll® DINCH®, only the
lungs showed any treatment-related weight changes although
there were no histopathologic changes (vide infra). The abso-
lute lung weights of mid- and high-dose males were signiﬁcantly
higher than for the control group the day following injection
(1.22±0.08g, 1.15±0.06g for mid- and high-dose, respectively,
versus 1.04±0.05g for the control group), but no difference was
seen for female rats or after 14 days of recovery. Dose-related
increases in absolute liver, lungs and spleen weight were observed
for both males and females at the end of 5 days of treatment
(Table 3), and for males at the end of 5 days of recovery (data not
shown). Statistically signiﬁcantdifferences in liver, lung, and spleen
weight were noted for the high-dose and mid-dose groups after 5
days of treatment compared with the control group. Statistically
signiﬁcant differences in liver and spleen weight were noted only
for the high-dose groups after 5 days of recovery.
No histopathologic changes attributed to treatment were
observed after a single injection. After 5 days of injection, the lungs,
liver, and spleen were identiﬁed as potential target organs. Vac-
uolated interstitial histiocytes were present in all treated groups
but the highest incidence was in high-dose animals. Further, lung
microgranulomas were present in all treated groups but, in this
case, the highest incidence was in mid-dose animals. In the low-
dose group, trace amounts of Kupffer cell vacuolation in the liver
and were observed in all females but not males. In mid-dose ani-
mals, trace amounts of Kupffer cell vacuolation in the liver were
observed inallmalesand females. Livermicrogranulomas thatwere
detected in all high-dose animals were not seen in either the low-
or mid-dose groups. In the low-dose group, reticuloendothelial cell
vacuolation in the spleen were observed in all females but not
males. In mid-dose animals, reticuloendothelial cell vacuolation in
the spleen were observed in all males and females.
104 R.M. David et al. / Toxicology Letters 238 (2015) 100–109
Table 2
Selected hematology values in animals 24h after a single injection or 5 days of injection with Hexamoll® DINCH® .
Parameter Males Females
Control Low Mid High Control Low Mid High
Single injection
HCT (%) 43.3 ± 0.8 42.6 ± 1.5 44.2 ± 2.7 41.2* ± 1.3 44.0 ± 3.4 44.2 ± 1.8 45.4 ± 1.5 41.6 ± 0.9
PLT (K/L) 929 ± 111 994 ± 116 867 ± 117 862 ± 76 1010 ± 86 792 ± 422 854 ± 178 815 ± 186
FIBR (mg/dL) 247 ± 32 266 ± 28 244 ± 45 311 ± 84 286 ± 79 242 ± 53 207 ± 113 228 ± 105
PT (s) 30 ± 2 30 ± 2 29 ± 3 29 ± 3 30 ± 2 35 ± 9 28 ± 2 29 ± 1
APTT (s) 53 ± 4 52 ± 2 51 ± 4 52 ± 9 48 ± 2 54 ± 11 57 ± 13 59 ± 22
5 days of injection
HCT (%) 45.2 ± 1.3 44.6 ± 2.4 44.3 ± 0.9 43.9 ± 1.1 44.0 ± 3.0 43.2 ± 1.4 43.2 ± 2.0 41.3 ± 2.4
PLT (K/L) 1114 ± 126 1122 ± 60 1033 ± 107 964 ± 87 1096 ± 163 867 ± 174 967 ± 65 756* ± 79
FIBR (mg/dL) 241 ± 36 349 ± 112 272 ± 37 231 ± 71 271 ± 61 236 ± 67 290 ± 13 281 ± 14
PT (s) 16.7 ± 0.2 17.0 ± 0.5 16.3 ± 1.1 17.5 ± 1.4 16.8 ± 1.1 16.6 ± 0.5 15.9 ± 0.4 16.2 ± 0.4
APTT (s) 13.7 ± 1.3 13.4 ± 1.8 14.0 ± 1.3 15.3 ± 1.9 13.5 ± 0.8 15.1 ± 2.5 14.5 ± 1.3 13.9 ± 1.1
Mean± standard deviation (n=5). HCT, hematocrit; PLT, platelet count; FIBR, ﬁbrinogen; PT, prothrombin time; APTT, activated partial thromboplastin time.
* Signiﬁcantly different from control, p≤0.05.
Table 3
Organ weights in rats injected repeatedly with Hexamoll® DINCH® for 5 days.
Dose group Males Females
Liver (g) Lungs (g) Spleen (g) Liver (g) Lungs (g) Spleen (g)
Control 5.75 ± 0.12 1.07 ± 0.04 0.49 ± 0.04 4.36 ± 0.19 0.92 ± 0.04 0.35 ± 0.03
Low 5.67 ± 0.34 1.15 ± 0.09 0.49 ± 0.03 4.57 ± 0.57 1.14* ± 0.09 0.44 ± 0.03
Mid 6.82 ± 0.21 1.41* ± 0.09 0.58 ± 0.06 5.05* ± 0.25 1.19* ± 0.09 0.46 ± 0.07
High 6.89* ± 0.59 1.33* ± 0.05 0.61 ± 0.07 5.67* ± 0.35 1.15* ± 0.14 0.56* ± 0.15
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Values provided as mean± standard deviation (n=5).
* Signiﬁcantly different than control, p<0.05.
Upon microscopic examination of target tissues from all recov-
ry animals, no indication was evident that these effects had
eversed over this short time span. However, it was noteworthy
hat a reduced incidence of liver microgranulomas and vacuolated
nterstitial histiocytes in the lungswas detected in high-dosemales
nd females. Examinationof the target tissuesdetermined that they
ad the morphologic characteristics of an oil/lipid-like material.
nterstitial histiocytes in the lungs as well as reticuloendothelial
ells in liver and spleen had engulfed this material. In some cases,
ultiple histiocytes surrounded the engulfed material resulting in
he formation of a microgranuloma.
.2. 4-Week study in-life measurements
For the 4-week study, thirteen unscheduled deaths occurred,
one of which were considered Hexamoll® DINCH®-related since
ost occurred in the control group. These included six control ani-
als, one female from the low dose, one male and one female from
he mid dose, and four females from the high dose. The causes
f death or early sacriﬁce of these animals included sepsis (ﬁve
nimals) or damaged or retracted catheter (ﬁve animals); cause
f death was undetermined for three animals. No clinical signs
f toxicity were observed in surviving animals. In addition, no
able 4
igniﬁcant serum chemistry and thyroxine levels in rats after 29 days of infusion of Hexa
Parameter Dose group males
Control
N=12
Low
N=15
Mid
N=9
High
N=15
ALB (g/dL) 3.9 ± 0.22 3.9 ± 0.19 3.3* ± 0.37 3.5* ± 0
GLOB (g/dL) 2.7 ± 0.25 2.9 ± 0.17 3.3* ± 0.16 3.5* ± 0
T3 (ng/dL) 122 ± 16 145* ± 22 136 ± 22 123 ± 2
T4 (g/dL) 7.2 ± 1.3 6.6 ± 1.1 5.6* ± 1.3 4.1* ± 1
TSH (IU/mL) 0.8 ± 0.7 0.6 ± 0.4 1.2 ± 1.2 0.7 ± 0
alues provided as mean± standard deviation. ALB, albumin; GLOB, globulin; T3, triiodot
* Signiﬁcantly different than control, p<0.05.differences were observed among groups in the functional
observational battery (data not shown). Body weight and feed con-
sumption: all surviving animals gained weight, and there were no
differences in mean body weight among groups.
3.3. Serum chemistries and hematology
There was a shift in protein from albumin to globulin in treated
animals (Table 4). A minimal decrease in albumin concentration
and minimal increase in globulin concentration were observed in
animals given the mid- and high-dose compared with the control
group. Mean albumin-to-globulin ratios in females given the low
dose and animals given mid- and high-dose were lower than for
control animals (decrease of 0.5). Total protein was not substan-
tially altered.
3.3.1. Tri-iodothyronine (T3), tetra-iodothyronine (T4), and
thyroid stimulating hormone (TSH) levels
Serum levels of T3, T4, and TSH were determined because
changes in these hormone levels were observed in oral toxicity
studies. The levels of T3 were unaffected after 29 days of exposure
(Table 4). Male rats of the mid- and high-dose groups had lower
T4 levels than did the control group after 29 days of infusion. No
moll® DINCH® .
Dose group females
Control
N=12
Low
N=14
Mid
N=9
High
N=11
.33 4.4 ± 0.39 4.2 ± 0.72 3.6* ± 0.24 3.6* ± 0.41
.40 2.6 ± 0.24 3.1* ± 0.44 3.2* ± 0.22 3.2* ± 0.35
4 167 ± 13 168 ± 26 158 ± 28 159 ± 31
.1 5.9 ± 1.2 5.5 ± 2.1 4.8 ± 1.5 4.2 ± 1.3
.5 0.2 ± 0.1 0.3 ± 0.2 0.3 ± 0.1 0.6* ± 0.5
hyronine; T4, thyroxine; TSH, thyroid stimulating hormone.
R.M. David et al. / Toxicology Letters 238 (2015) 100–109 105
Table 5
Hematology parameters in rats after 29 days of infusion with Hexamoll® DINCH® .
Parameter Dose groups (males) Dose groups (females)
Control
N=12
Low
N=15
Mid
N=9
High
N=14
Control
N=12
Low
N=14
Mid
N=9
High
N=11
RBC (106/L) 8.64 ± 0.31 8.33 ± 0.39 8.07* ± 0.53 8.17* ± 0.60 8.00 ± 0.58 7.74 ± 0.45 7.13* ± 0.59 7.23* ± 0.53
HGB (g/dL) 15.8 ± 0.7 15.2 ± 0.6 14.6* ± 0.9 13.2* ± 1.12 14.6 ± .1.0 14.3 ± 0.9 12.4* ± 1.3 12.6* ± 0.9
HCT (%) 51.6 ± 2.2 50.5 ± 2.1 48.8* ± 2.8 45.4* ± 3.3 47.8 ± 2.6 46.5 ± 2.7 41.6* ± 3.9 42.5* ± 2.9
MCV (fL) 59.7 ± 2.4 60.6 ± 1.4 60.6 ± 1.5 55.6* ± 2.3 59.9 ± 1.9 60.0 ± 1.1 58.4 ± 1.8 58.8 ± 1.9
Retic (103/L) 226.1 ± 32.3 257.9 ± 54.9 290.3* ± 64.4 487.2* ± 85.9 226.2 ± 96.8 216.2 ± 36.8 397.4* ± 149.3 429.6* ± 149.2
FIBR (mg/dL) 294 ± 35 295 ± 30 386 ± 138 348* ± 78 220 ± 30 305* ± 126 261 ± 99 331* ± 139
PT (s) 9.7 ± 0.4 9.5 ± 0.3 9.2* ± 0.5 8.7* ± 0.3 9.3 ± 1.7 8.8 ± 0.2 8.8 ± 0.7 8.5 ± 0.3
APTT (s) 18.4 ± 1.1 17.7 ± 1.0 16.9* ± 1.3 16.1 ± 1.2 17.9 ± 1.6 16.8 ± 1.8 15.8* ± 1.9 15.2* ± 1.1
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Values provided as mean± standard deviation. RBC, red blood cell count; HGB, he
IBR, ﬁbrinogen; PT, prothrombin time; APTT, activated partial thromboplastin tim
* Signiﬁcantly different than control, p<0.05.
ffect was seen in female rats. In judging the biological signiﬁcance
f these isolated ﬂuctuations in T3 and T4 levels, the levels of TSH
re of interest. After 29 days of infusion, the high-dose females had
igniﬁcantly higher levels of TSH compared with the control group,
ut no effect was seen in male rats after 29 days suggesting that
he T4 and TSH levelswere unrelated events. By contrast, bothmale
nd female rats treated orally with Hexamoll® DINCH® had altered
evels of TSH.
.4. Hematology
After 29 days of infusion, statistically signiﬁcant or other-
ise noteworthy hematology changes included higher absolute
eticulocyte and neutrophil counts for animals in the mid- and
igh-dose groups compared with the control group (Table 5). Min-
mally decreased red cell mass (decreased red blood cell count,
emoglobin concentration, and/or hematocrit) also was present in
id-dose females andhigh-dosemales and females comparedwith
he control group. All hematology changes were of small magni-
ude.Occasional differences were noted in coagulation parameters
Table 5). After 29 days of infusion, ﬁbrinogen concentration was
igher in mid- and high-dose males and females in all treated
roups compared with the control group. In addition, prothrombin
able 6
rgan weights and organ-to-body weight ratios in rats infused for 29 days with Hexamol
Dose group
Control Low
Males
Liver
Weight (g) 10.22 ± 1.25 (9) 11.69 ± 1.42 (1
Ratio (%) 2.63 ± 0.15 2.81 ± 0.21
Spleen
Weight (g) 0.835 ± 0.137 (9) 1.046* ± 0.144 (
Ratio (%) 0.22 ± 0.03 0.25* ± 0.02
Kidneys
Weight (g) 2.43 ± 0.30 (9) 2.53 ± 0.14 (1
Ratio (%) 0.627 ± 0.066 0.611 ± 0.039
Females
Liver
Weight (g) 6.99 ± 0.54 (9) 8.03 ± 1.01 (1
Ratio (%) 2.84 ± 0.11 3.09* ± 0.25
Spleen
Weight (g) 0.594 ± 0.117 (9) 0.844* ± 0.213 (
Ratio (%) 0.24 ± 0.04 0.32* ± 0.07
Kidneys
Weight (g) 1.54 ± 0.10 (9) 1.64 ± 0.87 (1
Ratio (%) 0.626 ± 0.029 0.635 ± 0.032
alues provided as mean± standard deviation (n).
* Signiﬁcantly different than control, p≤0.05.bin; HCT, hematocrit; MCV, mean corpuscular volume; Retic, reticulocyte count;
time was shorter for high-dose males, while activated partial
thromboplastin time was shorter in mid-dose females and all high-
dose groups compared with the control group. All coagulation
changes reversed by day 15 of the recovery phase in animals and
were not considered adverse.
3.5. Organ weights
After 29 days of infusion, organ weight increases were seen in
the liver of mid-dose and high-dose males and all treated groups
of females compared with the control group (Table 6). Spleen
weights for all treated males and females groups were signiﬁ-
cantly higher than for the control group, and the kidneyweights for
mid- and high-dose females groups were signiﬁcantly higher than
for the control group. Mean absolute and relative spleen weights
remained elevated at the recovery sacriﬁce in all treated groups of
males and high-dose females compared with the control groups.
Liver and kidney weight changes resolved during the recovery
phase.3.6. Histopathology
In the 4-week study, microgranulomas were noted in the
liver, spleen, and lungs in all groups given Hexamoll® DINCH®
l® DINCH® .
Mid High
0) 13.41* ± 2.84 (9) 13.15* ± 1.51 (10)
3.24* ± 0.46 3.67* ± 0.19
10) 1.628* ± 0.310 (9) 2.017* ± 0.545 (10)
0.39* ± 0.06 0.56* ± 0.13
0) 2.62 ± 0.26 (9) 2.36 ± 0.34 (10)
0.639 ± 0.042 0.658 ± 0.045
0) 11.14* ± 2.35 (9) 10.36* ± 1.45 (8)
4.34* ± 0.80 4.13* ± 0.42
10) 2.146* ± 1.024 (9) 1.663* ± 1.010 (8)
0.84* ± 0.39 0.66* ± 0.39
0) 1.74* ± 0.14 (9) 1.75* ± 0.12 (8)
0.680* ± 0.044 0.700* ± 0.544
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Table 7
Incidence and severity of microgranulomas in rats infused with Hexamoll® DINCH® for 29-days.
Dose group
Males Females
Control Low Mid High Control Low Mid High
Liver
Number examined 12 10 10 10 12 11 10 12
Microgranulomas
Not present 12 0 0 1 12 1 1 0
Minimal 0 10 3 0 0 9 1 1
Slight 0 0 4 0 0 1 1 1
Moderate 0 0 3 9 0 0 3 9
Marked 0 0 0 0 0 0 4 1
Spleen
Number examined 12 10 10 10 12 11 10 12
Microgranulomas
Not present 12 8 2 0 12 11 2 0
Minimal 0 2 4 0 0 0 2 2
Slight 0 0 4 1 0 0 0 4
Moderate 0 0 0 9 0 0 2 5
Marked 0 0 0 0 0 0 2 0
Severe 0 0 0 0 0 0 2 1
Oil red O-staining, increased
Number examined 5 0 0 5 5 0 0 5
Not present 5 0 0 4 5 0 0 4
Present 0 0 0 1 0 0 0 1
Lung
Number examined 12 10 10 10 12 11 10 12
Microgranulomas
Not present 12 0 0 0 12 2 1 0
Minimal 0 9 8 0 0 9 0 4
Slight 0 1 2 6 0 0 5 2
Moderate 0 0 0 4 0 0 0 4
Marked 0 0 0 0 0 0 3 2
Severe 0 0 0 0 0 0 1 0
Oil red O-staining, increased
Number examined 5 0 0 5 4 0 0 4
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Table 7). Microgranulomas were characterized microscopically by
he presence of small aggregates of vacuolated macrophages and
ymphocytes, typically disseminated throughout the parenchyma
f affected organs. In addition, morphologically similar intravascu-
ar granulomaswere noted less consistently in the brain, lungs, and
idneys. Intravascular granulomas occupied varying proportions of
he vascular lumen in which they occurred, sometimes appearing
o completely occlude the vessel, and other times eroding through
nd involving the vessel wall and perivascular tissue. These granu-
omatous lesions were most likely the result of the physical nature
f the Hexamoll® DINCH®, an oily substance requiring sonication
rior to intravenous administration, or the combination of test arti-
le and vehicle control article (Intralipid®), rather than evidence of
rgan-speciﬁc toxicity. This conclusion is supported by the pres-
nce of oil redO-positivematerial (lipophilicmaterial)within these
ranulomatous lesions.Whenmicrogranulomaswere present in oil
ed O-stained section of the lung and spleen, ﬁne oil red O-positive
roplets were present within the cytoplasm of macrophages mak-
ng up the microgranulomas in those organs, or particularly in
he lungs, as small oil red O-positive pools within granulomatous
esions. The oil red O-positive material was most easily demon-
trated in the lungs, less so in the spleen, and was not conclusively
emonstrated in the liver in the specimens examined. The pres-
nceofmicrogranulomas correlatedwith the increasedmeanorgan
eights in the liver and spleen.
Biochemical determination of cyanide-insensitive palmitoyloA oxidation enzyme activity did not show any treatment-related
ncrease (data not shown). In addition, staining of the liver for lipo-
uscin failed to show any treatment-related effect. Thus, there was
o evidence of peroxisome proliferation.1 4 0 0 0
4 0 0 0 4
3.7. Metabolite determination
Blood collected approximately 2h after a single injection of
Hexamoll® DINCH® showed measurable levels of Hexamoll®
DINCH® and the respective monoester MINCH. Concentrations of
Hexamoll® DINCH® were 2.87±1.43g/mL for females injected
with 300mg/kg Hexamoll® DINCH® and 4.86±1.30g/mL for
males given the same dose level. Concentrations of the monoester
MINCH in the same animals were 4.16±1.17g/mL for females
and 3.28±0.46g/mL for males. For contrast, Zhong et al. (2013)
measured the concentrationofHexamoll® DINCH® in 715mLblood
stored in PVC bags to be 0.673±0.084g/mL (almost 100 times
lower than DEHP) after 6h in a 37 ◦C bath. Given that this repre-
sents approximately 1/7th of the total volume of blood, exposure
of a patient to Hexamoll® DINCH® following one transfusion might
be in the order of 0.08g/mL. Thus, the highest dose level used
in the current study is at least 50 times above anticipated human
exposure levels.
Urinary metabolite levels were also determined at weekly
intervals of the 4-week study. Cyclohexane-1,2-dicarboxylic acid
(CHDA) was the primary metabolite, with much smaller concen-
trations of other metabolites detected. Fig. 1a–d provides the
excreted amounts of all metabolites for male and female rats
from each sampling day. The amounts excreted for the low and
mid-dose groups were very consistent, and show a good dose-
relationship. At the high dose, the amounts excreted deviated from
the dose–response andwere similar to the amounts excretedby the
mid-dose group suggesting that not all theHexamoll® DINCH® was
bioavailable. Indeed, it is possible that some Hexamoll® DINCH®
was sequestered in granulomas and slowly released because
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Fig. 1. Excreted amounts of all metabolites in the urine of rats administered Hexamoll® DINCH® via intravenous infusion. Data presented as mean and standard deviation
(n=9–15, depending on number of survivors). Filled squares represent male rats, ﬁlled diamonds represent female rats. Panels depict the excreted amount after 7 (a), 14 (b),
21 (c), and 28 (d) days.
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ga) Urinary amounts of all metabolites from intravenous infusion of Hexamoll DI
examoll® DINCH® after 14 days. (c) Urinary amounts of allmetabolites from intrav
rom intravenous infusion of Hexamoll® DINCH® after 28 days.
etabolites could be detected in the urine of the low-dose and
igh-dose groups 14 days following the last infusion albeit at lev-
ls 10 times lower than during treatment for the low-dose group
nd 3 times lower than during treatment for the high-dose group.
. Discussion
The data presented here demonstrate that single or repeated
ntravenous exposure to Hexamoll® DINCH® does not produce
ystemic toxicity. The effects observed in rats are considered a
eﬂection of physiological reactions to a hydrophobic, lipid-like
ubstance or to the inﬂammation associated with granulomas
ather than inherent toxicity. For example, none of the effects
bserved in oral toxicity studies of Hexamoll® DINCH® was evi-
ent here (EFSA, 2006; Australian National Industrial Chemicals
otiﬁcation and Assessment Scheme (NICNAS), 2012; Bhat et al.,
014). Rather, organ weight changes and histopathologic ﬁnd-
ngs in those target organs are all associated with the presence
f a hydrophobic substance, namely the plasticizer. Furthermore,
pparent changes in ﬁbrinogen concentration, prothrombin time,
nd hematologic effects have been observed with granulomatous
nﬂammation. These ﬁndings emphasize the difﬁculty in solu-
ilizing a hydrophobic substance such as a plasticizer, and the
ose–response reinforces the limits of solubilization observed by
ubin (1975) and Schulz et al. (1975).
Bhat et al. (2014) reported what had been reviewed by the
ndependent National Sanitation Foundation (NSF) Health advi-
ory board and by regulatory bodies such as EFSA and NICNAS on
he toxicology of Hexamoll® DINCH®. They all concluded that tar-
et organs from oral administration were the thyroid gland andafter 7 days. (b) Urinary amounts of all metabolites from intravenous infusion of
infusion of Hexamoll® DINCH® after 21 days. (d) Urinary amounts of allmetabolites
the kidneys. Neither of these organs were identiﬁed in the stud-
ies of Hexamoll® DINCH® administered by either IV injection or
IV infusion. There was no effect on circulating thyroid hormones
or thyroid stimulating hormone, and no effect on the kidneys. In
addition, there were no effects on reproductive organs or evidence
of liver peroxisomal enzyme induction that have been associated
with phthalic acid esters. Instead, histopathologic ﬁndings were
associated with granulomas that likely formed as the hydrophobic
plasticizer dissipated from the suspension.
Granulomas are not uncommon in studies that use high
hydrophobic or lipid materials either by injection (Rubin, 1975;
Schulz et al., 1975) or infusion (Nordstrand et al., 1987). Indeed,
granulomaswereobserved in thepreliminary studies ofHexamoll®
DINCH® conducted by IV injection, and are considered to be a
foreign-body reaction. This conclusion is supported by the posi-
tive oil red O stain observed in the granulomas observed after 4
weeks, demonstrating that the material associated with the gran-
uloma was lipid-like. Furthermore, the principal organs associated
with granulomas are the lungs, liver, and spleen (Nordstrand et al.,
1987), the same organs identiﬁed as target organs in the current
study. Nordstrand and coworkers reported enlarged liver, spleen,
and lungs of rats infused with a mixture of nutrients suspended
in Intralipid® and they showed enlarged Kupffer cells in the liver,
and eosinophils and enlarged white and red pulp in the spleen. The
lungs also demonstrated granulomas and “vascular inﬂammation”.
As was observed in the study presented here, these lesions were
not readily reversible within 36 days following the last infusion.
Hematologic effects observed in the current study that appear
to be associated with treatment are an increase in ﬁbrinogen, a
decrease in activated partial thromboplastin time, and a decrease
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n prothrombin time. While Zhong et al. (2013) described changes
n coagulation parameters (PT and APTT) in blood stored in PVC
lasticized with Hexamoll® DINCH®, there was no difference
hen compared to blood stored in PVC plasticized with DEHP.
hus, changes in coagulation parameters may not be related to
examoll® DINCH®, but rather to granuloma formation. Wiseman
nd Chang (1968) ﬁrst describe increased serum ﬁbrin levels
nd reduced prothrombin time following induction of edematous
nﬂammation. Izaki et al. (1979) took that further to induce gran-
lomas in laboratory animals and measure ﬁbrin deposition and
-cell function. Their results show that ﬁbrin is deposited prior to
ranuloma formation, and that clotting is activated. In the present
tudy, increased serum ﬁbrinogen and lower prothrombin time
ere evident primarily in the highest dose group. This dose group
lso had the highest incidence of granulomas. Thus, the hemato-
ogic changes observed in the present study are likely the result
f the granulomas rather than any inherent toxicity of Hexamoll®
INCH®.
A key aspect of the studies presented here is the inclusion of
lood levels following injection and urinary metabolites following
epeated infusion. These data show that Hexamoll® DINCH® was
ioavailable. In addition, theblood samplesdemonstrate thatmolar
onoester concentrations exceeded the molar concentrations of
he parent compound Hexamoll® DINCH® in the blood, suggest-
ng substantial hydrolysis of the di-ester within 2h post dosing.
rinary excretion of metabolites shows a dose-related increase for
he low- and mid-dose groups, but not for the high-dose group.
wophenomena could account for the lack of dose–response in uri-
ary excretion at the high-dose: one is that the granulomas act as
reservoir of Hexamoll® DINCH® that is released slowly over time.
he detection of urinary metabolites 14 days after the last infu-
ion would support this hypothesis, especially since the terminal
alf-life of Hexamoll® DINCH® is ∼2 days after oral administration
Bhat et al., 2014). Second, elimination processes may have been
aturated and shifted from urinary excretion to biliary excretion,
oted as higher at high dose levels compared with lower dose lev-
ls after oral administration (Bhat et al., 2014). Biliary excretion
as not investigated as part of this study.
Injection or infusion of a hydrophobic substance such as
examoll® DINCH® canbeproblematic. Rubin (1975) reported that
% gum acacia, 4% serum albumin, or Tween 20 was inadequate to
olubilize DEHP, but solubilization in Tween 80 produced a trans-
arent suspension. Schulz et al. (1975) reported hemorrhagic lungs
n rats injectedwith >300mg/kgDEHP solubilized in Tween 80, and
he severity of hemorrhagic lungs increased in a dose-related man-
er from 50 to 250mg/kg DEHP. On the other hand, Wirnitzer et al.
2011) infused 380mg/kg di(2-ethylhexyl) terephthalate (DEHT),
nother hydrophobic substance, suspended in Lipofundin MCT10
ithout any apparent effect on the lungs or other organs, although
foreign-body reactions” were noted that were conﬁrmed by oil
ed O stain as lipophilic positive. There are signiﬁcant differences
etween the present study of Hexamoll® DINCH® and the study
f DEHT reported by Wirnitzer et al. First, the infusion times were
igniﬁcantly different: the present study used 4h into the femoral
ein, while Wirnitzer et al. used 12h into the vena cava. This differ-
nce alone could account for the higher incidence of granulomas
or foreign-body reactions) in the present study because the test
ubstance was more concentrated (25mg Hexamoll® DINCH®/mL
ntralipid® versus 15.9mg DEHT/mL Lipofundin MCT10) and less
ikely to maintain the suspension in the blood. Also, Wirnitzer and
oworkers did notmeasure blood levels of DEHTor urinary levels of
etabolites, so it is difﬁcult to determine if DEHT was completely
ioavailable. The lack of information regarding bioavailability is
nfortunate especially when no remarkable ﬁndings are observed.
In summary, rats were infused with Hexamoll® DINCH® sus-
ended in Intralipid® without apparent systemic effects identiﬁedters 238 (2015) 100–109
up to the highest dose tested. Keeping in mind the physical limi-
tations, we consider the no-observed-adverse-effect level (NOAEL)
systemic toxicity to be 300mg/kg bw/day. These data along with
the data of erythrocyte survival support the use of Hexamoll®
DINCH® as a plasticizer for medical applications especially in blood
collection and storage bags. Further studies may support further
speciﬁc applications in the medical ﬁeld.
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